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progression is a150,000–350,000 for each therapy but glatiramer acetate (a651,796). 
Probabilistic sensitivity analysis conﬁrmed subcutaneous interferon beta-1a and inter-
feron beta-1b as the most cost-effective therapies (conﬁdence intervals remained below 
a45,000 per avoided relapse). Estimated budget impact of assuming 5–9% annual 
increase of subcutaneous interferon beta-1a market share equals 0.17–0.52% of actual 
RRMS cost in Spain. CONCLUSIONS: Subcutaneous interferon beta-1a is an efﬁcient 
strategy for RRMS in Spain as it allows an appropriate management and treatment 
of RRMS relapses and progression with a minor budgetary impact for SNHS.
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OBJECTIVES: Economic evaluation of Lacosamide (LCM) and standard treatment 
with commonly used antiepileptic drugs (ST) vs. ST alone in the Finnish setting. LCM 
is a new antiepileptic drug, indicated for adjunctive treatment of partial-onset seizures 
(POS) with or without secondary generalisation in patients aged 16 years and older. 
METHODS: A probabilistic decision tree based cost-effectiveness analysis (CEA) with 
second-order Monte Carlo simulation and a 2-year time-frame was performed in Excel 
from the Finnish societal perspective (productivity losses and VAT excluded). The 
efﬁcacy data were obtained from the LCM-trials, and the Finnish costs (inpatient, 
outpatient, GP, laboratory, drug) and utilities from published studies. Budget impact 
modelling (BIM) with a ﬁve year time-frame was done to assess the net monetary 
impact of LCM launch to the refractory epilepsy budget. Only drug costs were 
included in BIM. Conservatively, generic prices were used in all analyses. RESULTS: 
According to CEA, LCMST was associated with an incremental cost of a945 (mainly 
related to seizure management and drug acquisition), a gain of 0.040 QALYs and 8.92 
seizures avoided compared to ST alone. LCMST was associated with a cost of 
a23,396 per QALY gained and a106 per seizure avoided compared to ST alone. 
According to the cost-effectiveness acceptability frontier, the probability of LCM’s 
cost-effectiveness was 67.9% and 85.6% with a30,000 and a50,000 per QALY 
gained, respectively. The results were robust in sensitivity analyses. According to BIM, 
the expected annual budget increase due to launch of LCM is a0 in 2008, a7,653 in 
2009, a47,350 in 2010, a134,949 in 2011, and a232,609 in 2012. The relative 
increase in the annual epilepsy budget due to LCM is 0.08% in 2009, 0.46% in 2010, 
1.31% in 2011, and 2.23% in 2012. CONCLUSIONS: LCM is a valuable option for 
POS treatment because of its potential cost-effectiveness and low budget impact.
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OBJECTIVES: Neurostimulators (NS) for DBS are replaced when the battery goes to 
an end-of-life (EOL). Activa® RC, Medtronic’s new rechargeable NS, offers guaranteed 
9 years longevity. The objective was to perform a cost analysis of Activa® RC, vs. 
Kinetra® (previous non-rechargeable NS), based on the number of EOL replacements 
needed. METHODS: The following costs were included (hospital perspective, a, 
2009): 1) DBS acquisition costs; 2) surgical procedure cost: Spanish tariff for Parkin-
son disease surgery; 3) EOL NS’s replacement procedure cost: includes surgical pro-
cedure cost (excluding the acquisition costs of therapy components) and the NS cost. 
The EOL depends on patient energy requirements (disease-related) and on the NS: 
Kinetra®: dystonia patients replacements every 2 years; Parkinson disease, every 3–4 
years; essential tremor, every 4–5 years(expert opinion). Activa® RC: every 9 years for 
all indications. Cumulative costs/year was obtained for a 9-years timeframe to 
compare the costs and number of surgical replacements avoided with Activa® RC. The 
main cost driver, surgical procedure cost, was changed as a sensitivity analysis (SA). 
RESULTS: Thanks to higher battery longevity, the following savings could be 
obtained: 1) Dystonia patients, as higher energy requirement are needed, higher eco-
nomic beneﬁts are observed: at year a9, 57.585 saved/patient or 4 EOL-replacement 
avoided; 2) Parkinson disease, at year 9, 2 replacements are avoided, that represents 
a21.867 saved/patient; 3) Essential tremor, savings oscillates between a4.008-a21.867, 
avoiding 1–2 EOL-replacement in 9 years. CONCLUSIONS: Although initial acquisi-
tion costs of Activa® RC are higher, compared to Kinetra®, those are compensated 
after the ﬁrst Kinetra®’s EOL surgical replacement, obtaining important cost savings 
at year 9 (4.008a-57.585a/patient), avoiding 1–4 surgical replacements. The more 
energy requirements, the higher economic beneﬁts are observed with Activa® RC. An 
adequate patient selection is needed to maximize clinical and economic beneﬁts of 
Activa® RC-DBS.
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OBJECTIVES: Activa®, Medtronic’s DBS, is an effective,safe and reversible therapy 
for Parkinson disease, essential tremor and dystonia. A cost analysis was perform to 
estimate the economic beneﬁts related to 2 features of Activa PC® family, new DBS 
generation devices, and the net Budget impact (BI) for Spanish hospitals, compared 
to Kinetra®. METHODS: The 2 features: neurostimulator’s (NE) lower size and new 
stretchable extensions; both can avoid some adverse events (AEs) associated with 
Kinetra (no other beneﬁts were considered). A literature search was done to retrieve 
safety studies. Selection criteria: AEs related with NE &/or the extension, their inci-
dence and detailed treatment description. Health resource use was assigned to AEs 
treatment (Spanish hospital costs, Euros 2009): regional tariffs; acquisition costs. A 
net cost for each AEs was obtained, multiplying each AEs treatment incidence by its 
total cost. Total cost obtained with Activa PC®, compared to Kinetra®, corresponds 
to savings/patient. The net BI for Spanish hospitals was calculated: total incremental 
cost/Activa PC® treated patient instead of Kinetra® (considering AEs avoided and its 
savings). An AE incidence comparison was made as a sensitivity analysis (SA). 
RESULTS: 2 safety studies were selected. The 2 features could avoid 6 AEs, 2 related 
to NEs (hematoma in the NE implant site; infection/erosion); 4 with the extension 
(lead broke after a fall; extension fracture; skin ulceration in the connector; local dis-
comfort). In total, avoiding these AEs involved 591a saved/patient treated with Activa 
PC® family (SA obtained similar data). Including Activa PC® instead of Kinetra family 
in Spanish Hospitals involved a net BI per patient of a1.781. CONCLUSIONS: The 
new Activa PC family may avoid AEs related to the previous generation, Kinetra, with 
a decrease in the total cost per patient. The substitution of Kinetra® for Activa PC® 
family involves a small net budget impact per patient.
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OBJECTIVES: To examine the economic burden of newly diagnosed multiple sclerosis 
(MS) on the US health care system using a large, managed care database. METHODS: 
This was a retrospective cohort analysis of a large, US claims database. Cases were 
deﬁned as having either an MS diagnosis (ICD-9-CM 340) on at least 2 claims or 1 
prescription for MS treatment (glatiramer acetate, interferon betas, or natalizumab) 
between 2004 and 2006. The index date was the ﬁrst qualifying diagnosis or prescrip-
tion. We excluded patients with an MS diagnosis or treatment over the 12 month 
pre-index period, or without continuous enrollment from 12 months pre- to 12 
months post-index date. Each case had 5 controls without MS diagnoses or treatment 
matched on geographic region, insurance type, gender, relation to employee, age and 
lack of comorbid conditions with a similar period of continuous enrollment. Use of 
services was compared using chi-square tests, and 2008 adjusted costs were compared 
using the Wilcoxon rank-sum nonparametric tests. RESULTS: There were 1412 cases 
and 7,060 matched controls in the study. Sixty-six percent of the study population 
was female. MS patients were twice as likely to have emergency department (ED) visits 
(25.5% vs. 12.2%), 1.3 times as likely to have physician ofﬁce visits (95.8% vs. 
75.1%), and 2.4 times as likely to have used physical therapy (all p-values 0.001) 
services over the follow-up period. MS patients also had higher costs related to these 
services ($380 vs. $166, $614 vs. $228, and $268 vs. $74, respectively; all p-values 
0.001). Total costs for MS patients were signiﬁcantly higher than for controls 
($16,984 vs. $3,639 p  0.001). CONCLUSIONS: Newly diagnosed MS patients 
present a large burden on the health care system with additional 1st-year cost of over 
$13,000. While MS treatment drugs are expensive, this represents only one-third of 
the additional cost of care within the 1st year.
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OBJECTIVES: Migraine is prevalent, and headache-related disability can impact the 
ability of migraineurs to work and perform daily activities. This study examined the 
impact of CM compared to EM on work patterns and productivity across countries. 
METHODS: Web-based survey data were collected from migraineurs in the US, 
Canada, Germany, UK, France, Italy, Spain, Australia, and Taiwan. According to 
ICHD-2 criteria, presence of migraine (past 3-months headaches with pain, nausea, 
and photophobia/phonophobia) and q15 headache days/month indicated CM, and 
14 headache days/month indicated EM. Questions on absenteeism and presenteeism 
(reduced efﬁciency) in the preceding 4 weeks assessed headache impact on work or 
school. Linear and logistic regressions, as appropriate, compared migraine group and 
adjusted for age, gender, race, education, comorbidities, and country. RESULTS: Of 
63,001 invitees, 20,987 responded. A total of 9,118 completers (14.5%) comprised 
the ﬁnal cohort [n  516 (Australia) to 1597 (US)]; 83.6% female; 5.5% CM, 90.2% 
EM. CM respondents were 1.4 times more likely than EM to report that they had 
missed any work/school due to headache (95% CI  1.1, 1.8). CM reported missing 
a higher number of work/school days due to headache symptoms than EM (adjusted 
mean o SE  8.83 o 0.59 vs. 4.05 o 0.44, p  0.0001), as well as working more days 
